Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis

Department of Ophthalmology, Medical College of Georgia, Augusta, GA 30912, USA.
Molecular vision (Impact Factor: 1.99). 02/2008; 14:2190-203.
Source: PubMed


Degenerative retinal diseases are characterized by inflammation and microglial activation. The nonpsychoactive cannabinoid, cannabidiol (CBD), is an anti-inflammatory in models of diabetes and glaucoma. However, the cellular and molecular mechanisms are largely unknown. We tested the hypothesis that retinal inflammation and microglia activation are initiated and sustained by oxidative stress and p38 mitogen-activated protein kinase (MAPK) activation, and that CBD reduces inflammation by blocking these processes.
Microglial cells were isolated from retinas of newborn rats. Tumor necrosis factor (TNF)-alpha levels were estimated with ELISA. Nitric oxide (NO) was determined with a NO analyzer. Superoxide anion levels were determined by the chemiluminescence of luminol derivative. Reactive oxygen species (ROS) was estimated by measuring the cellular oxidation products of 2', 7'-dichlorofluorescin diacetate.
In retinal microglial cells, treatment with lipopolysaccharide (LPS) induced immediate NADPH oxidase-generated ROS. This was followed by p38 MAPK activation and resulted in a time-dependent increase in TNF-alpha production. At a later phase, LPS induced NO, ROS, and p38 MAPK activation that peaked at 2-6 h and was accompanied by morphological change of microglia. Treatment with 1 microM CBD inhibited ROS formation and p38 MAPK activation, NO and TNF-alpha formation, and maintained cell morphology. In addition, LPS-treated rat retinas showed an accumulation of macrophages and activated microglia, significant levels of ROS and nitrotyrosine, activation of p38 MAPK, and neuronal apoptosis. These effects were blocked by treatment with 5 mg/kg CBD.
Retinal inflammation and degeneration in uveitis are caused by oxidative stress. CBD exerts anti-inflammatory and neuroprotective effects by a mechanism that involves blocking oxidative stress and activation of p38 MAPK and microglia.

Download full-text


Available from: Azza B El-Remessy,

Click to see the full-text of:

Article: Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis

17.1 MB

See full-text
  • Source
    • "Herein, the p38-peak at 12 h after TGFβ1 treatment is dependent on NAD(P)H oxidase activity. El-Remessy et al. also showed a ROS-dependent p38 activation induced by NAD(P)H oxidase [52]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-stroma interaction is a prerequisite for tumor progression in skin cancer. Hereby, a critical step in stromal function is the transition of tumor-associated fibroblasts to myofibroblasts by growth factors, for example transforming growth factor beta (TGFβ). In this study, the question was addressed of whether fibroblast associated NAD(P)H oxidase, known to be activated by TGFβ1, is involved in the fibroblast-to-myofibroblast switch. The up regulation of alpha smooth muscle actin (αSMA), a biomarker for myofibroblasts, is mediated by a TGFβ1-dependent increase in the intracellular level of reactive oxygen species (ROS). The source of these ROS was identified to be NAD(P)H oxidase, showing two activity peaks over time with an early and late activity peak after treatment with the growth factor. The late (second) activity peak of NAD(P)H oxidase was identified to be responsible for the downstream signaling resulting in reactive oxygen species triggered activation of the stress kinase p38 and expression of αSMA. These data suggest that inhibition of NAD(P)H oxidase activity prevents the fibroblast-to-myofibroblast switch and may be important for chemoprevention.
    Bioscience Reports 12/2013; 34(1). DOI:10.1042/BSR20130091 · 2.64 Impact Factor
  • Source
    • "Numerous studies have implicated activated p38 MAPK in RGC injury, especially in pathways relevant to glaucoma (El-Remessy et al., 2008; Harada et al., 2006; Kikuchi et al., 2000; Levkovitch-Verbin et al., 2007; Manabe and Lipton, 2003; Tezel et al., 2003). Here we tested whether a highly selective and potent inhibitor of the p38 MAPK catalytic domain (Ro3206145) could prevent degeneration with elevated IOP in an inducible model of glaucomatous optic neuropathy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The p38 mitogen-activated protein kinase (MAPK) isoforms are phosphorylated by a variety of stress stimuli in neurodegenerative disease and act as upstream activators of myriad pathogenic processes. Thus, p38 MAPK inhibitors are of growing interest as possible therapeutic interventions. Axonal dysfunction is an early component of most neurodegenerative disorders, including the most prevalent optic neuropathy, glaucoma. Sensitivity to intraocular pressure at an early stage disrupts anterograde transport along retinal ganglion cell (RGC) axons to projection targets in the brain with subsequent degeneration of the axons themselves; RGC body loss is much later. Here we show that elevated ocular pressure in rats increases p38 MAPK activation in retina, especially in RGC bodies. Topical eye-drop application of a potent and selective inhibitor of the p38 MAPK catalytic domain (Ro3206145) prevented both the degradation of anterograde transport to the brain and degeneration of axons in the optic nerve. Ro3206145 reduced in the retina phosphorylation of tau and heat-shock protein 27, both down-stream targets of p38 MAPK activation implicated in glaucoma, as well as well as expression of two inflammatory responses. We also observed increased p38 MAPK activation in mouse models. Thus, inhibition of p38 MAPK signaling in the retina may represent a therapeutic target for preventing early pathogenesis in optic neuropathies.
    Neurobiology of Disease 07/2013; 59. DOI:10.1016/j.nbd.2013.07.001 · 5.08 Impact Factor
  • Source
    • "Macrophages diminished release of NO, IL-12p40 and TNFα (Chuchawankul et al. 2004) Macrophages prevented ROS production and secretion of TNFα and CCL2 (Han et al. 2009) B and T cells affected B and T cell differentiation, and the balance of pro-inflammatory to anti-inflammatory cytokines (Ziring et al. 2006) Macrophages increased secretion of the anti-inflammatory cytokine, IL-10 (Correa et al. 2009) Macrophages (Kupffer cells) inhibited LPS-induced NF-kB activation (Louvet et al. 2011) Neuroimmune Microglia diminished levels of IL-1β, IL-6 and TNFα (Puffenbarger et al. 2000) Microglia inhibited release of TNFα (Facchinetti et al. 2003; Ramirez et al. 2005) Microglia diminished expression of CD40 (Engelhardt and Ransohoff 2005) Glia enhanced release of the anti-inflammatory factors, IL-4 and IL-10 (Molina-Holgado et al. 1998) Microglia inhibited TNFα production, p38 MAPK activation and NADPH oxidase (NOX) activation (El-Remessy et al. 2008) Microglia interfered with expression of CCR2 and iNOS (Racz et al. 2008) Microglia inhibited migration of microglial cells to HIV Tat protein (Fraga et al. 2011) 2007, 2008; Yiangou et al. 2006; Solas et al. 2012). Enhanced CB 2 expression was detected on microglia, perivascular macrophages and T cells in simian immunodeficiency virus encephalitis , a model of HIV-1 infection that paralleled FAAH over-expression in astrocytes (Benito et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB1, CB2) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB2 activation. Development of CB2 agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB2 activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.
    Journal of Neuroimmune Pharmacology 03/2013; 8(3). DOI:10.1007/s11481-013-9445-9 · 4.11 Impact Factor
Show more